Black Rock Inc. Adagio Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,473,808 shares of ADGI stock, worth $14.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,473,808

Previous 876,569 410.38%

Holding current value

$14.8 Million

Previous $2.9 Million 410.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	N/A	3,597,239 Added 410.38%	4,473,808 $14.8 Million
Q1 2024 May 10, 2024	SELL	N/A	-23,411 Reduced 2.6%	876,569 $2.9 Million
Q4 2023 Feb 13, 2024	SELL	N/A	-231,416 Reduced 20.45%	899,980 $2.98 Million
Q3 2023 Nov 13, 2023	SELL	N/A	-186,309 Reduced 14.14%	1,131,396 $3.74 Million
Q2 2023 Aug 11, 2023	SELL	N/A	-2,454,531 Reduced 65.07%	1,317,705 $4.36 Million
Q1 2023 May 12, 2023	SELL	N/A	-104,807 Reduced 2.7%	3,772,236 $12.5 Million
Q4 2022 Feb 13, 2023	BUY	$3.08 - $4.05 $1.22 Million - $1.61 Million	396,410 Added 11.39%	3,877,043 $12.8 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $1.13 Million - $1.84 Million	381,001 Added 12.29%	3,480,633 $10.9 Million
Q2 2022 Aug 12, 2022	BUY	$2.54 - $4.52 $376,013 - $669,127	148,037 Added 5.02%	3,099,632 $10.2 Million
Q1 2022 May 12, 2022	BUY	$3.81 - $10.77 $6.26 Million - $17.7 Million	1,644,328 Added 125.78%	2,951,595 $13.5 Million
Q4 2021 Feb 10, 2022	SELL	$6.35 - $47.04 $138,353 - $1.02 Million	-21,788 Reduced 1.64%	1,307,267 $9.49 Million
Q3 2021 Nov 09, 2021	BUY	$20.88 - $56.08 $27.8 Million - $74.5 Million	1,329,055 New	1,329,055 $56.1 Million

Others Institutions Holding ADGI

# of Institutions

Shares Held

63.9M

Call Options Held

2.3K

Put Options Held

2.1K

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account